Jpmorgan Chase & CO Maxcyte, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Maxcyte, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 209,572 shares of MXCT stock, worth $787,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares

209,572

Previous 241,572 13.25%

Holding current value

$787,990

Previous $1.01 Million 18.87%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.63 - $5.0 $116,160 - $160,000	-32,000 Reduced 13.25%	209,572 $821,000
Q1 2024 May 10, 2024	BUY	$3.94 - $5.38 $3,518 - $4,804	893 Added 0.37%	241,572 $1.01 Million
Q4 2023 Feb 12, 2024	SELL	$2.6 - $5.24 $304,584 - $613,855	-117,148 Reduced 32.74%	240,679 $1.13 Million
Q3 2023 Nov 14, 2023	SELL	$3.02 - $5.1 $9,999 - $16,886	-3,311 Reduced 0.92%	357,827 $1.12 Million
Q2 2023 Aug 11, 2023	SELL	$3.69 - $5.35 $69,065 - $100,135	-18,717 Reduced 4.93%	361,138 $1.66 Million
Q1 2023 May 18, 2023	BUY	$4.03 - $5.89 $272,069 - $397,639	67,511 Added 21.61%	379,855 $1.88 Million
Q1 2023 May 11, 2023	BUY	$4.03 - $5.89 $23,321 - $34,085	5,787 Added 1.89%	312,344 $1.55 Million
Q4 2022 Feb 13, 2023	BUY	$4.92 - $7.4 $185,961 - $279,697	37,797 Added 14.06%	306,557 $1.67 Million
Q3 2022 Nov 14, 2022	BUY	$4.52 - $6.51 $47,948 - $69,058	10,608 Added 4.11%	268,760 $1.75 Million
Q2 2022 Aug 11, 2022	BUY	$3.59 - $6.81 $535,864 - $1.02 Million	149,266 Added 137.08%	258,152 $1.22 Million
Q1 2022 May 11, 2022	BUY	$5.26 - $10.84 $40,223 - $82,893	7,647 Added 7.55%	108,886 $762,000
Q4 2021 Feb 10, 2022	BUY	$8.87 - $12.94 $723,907 - $1.06 Million	81,613 Added 415.84%	101,239 $1.03 Million
Q3 2021 Nov 12, 2021	BUY	$12.21 - $17.2 $239,633 - $337,567	19,626 New	19,626 $239,000

Others Institutions Holding MXCT

# of Institutions

118

Shares Held

65.1M

Call Options Held

600

Put Options Held

2.7K

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $382M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Maxcyte, Inc. Transaction History